




Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
-------------------	---	-----	-------------

Note: Timolol Maleate 0.68% is equivalent to Timolol 0.5%.

SUGGESTED FORMULATION

Ingredient Listing	Qty	Unit	NDC #	Supplier	Lot Number	Expiry Date
Timolol Maleate, USP	0.136	g				
Sodium Chloride, USP	0.16	g				
Sterile Water For Injection, USP	16.0	mL				
Sterile Water For Injection, USP	q.s. to 20.0	mL				
Sodium Hydroxide 5% Solution	As required					

MEDISCA®
NETWORK INC.



DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
-------------------	---	-----	-------------

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible):

Timolol Maleate

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error /

Testing Considerations:

To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **15 to 20%** of the required quantities of ingredients.

Special Instruction:

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
-------------------	---	-----	-------------

SUGGESTED PREPARATION (for 20 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Timolol Maleate, USP §	0.136	g			
Sodium Chloride, USP §	0.16	g			
Sterile Water For Injection, USP §	16.0	mL			
Sterile Water For Injection, USP §	q.s. to 20.0	mL			
Sodium Hydroxide 5% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1.	<p><u>Equipment sterilization:</u></p> <p>Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.</p>
2.	<p><u>Medium preparation:</u></p> <p>A. Incrementally add the Sodium Chloride to the following ingredient:</p> <ul style="list-style-type: none"> - Sterile Water For Injection (16.0 mL <i>plus</i> processing error adjustments) <p><u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.




Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
3.	<p><u>API to medium integration:</u></p> <p>A. Incrementally add the Timolol Maleate to the following ingredient:</p> <ul style="list-style-type: none">- Homogeneous liquid-like solution (Step 2A) <p><u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
4.	<p><u>pH testing:</u></p> <p>A. Draw an appropriate amount of the mixture (Step 3A).</p> <p>B. Test the pH of the sample. It should lie between 6.5 and 7.5.</p> <p>C. <u>If the pH < 6.5, carefully add in a dropwise manner the Sodium Hydroxide 5% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 5% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 5% Solution.3. Re-test the pH.4. Continue to add the Sodium Hydroxide 5% Solution until the pH of 6.5 to 7.5 is obtained. <p>IMPORTANT: Do not allow the pH to rise above 7.5.</p>		
5.	<p><u>Filling to volume:</u></p> <p>A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (20.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specification:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
6.	<p><u>Filtering and transferring:</u></p> <p>Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>		

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
7.	<u>Filter integrity test:</u> Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.		
8.	<u>Sterility testing:</u> Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.		



MEDISCA®
NETWORK INC.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
-------------------	---	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated. BUD based on a successful sterility and endotoxin test result.	Packaging Requirements	Sterile, light-resistant eye dropper bottle.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	7	Equilibrate to room temperature before use.
	2	Keep out of reach of children.	8	Cap tightly after use.
	3	Do not allow the dropper tip to come into contact with the body or any type of surface in order to prevent contamination.	9	For ophthalmic use only.
	4	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	10	Discard in the presence of particulate matter.
	5	Keep refrigerated. Do not freeze.	11	Do not use if discolored.
	6	Protect from light.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions. IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied.			

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Timolol Maleate 0.68% Ophthalmic Liquid (Solution, 20 mL)	FIN	F 000 095v2
-------------------	---	-----	-------------

REFERENCES

1.	2003 <i>Physicians Desk Reference</i> ®. Montvale, NJ: Medical Economics Company, Inc.; 2003
2.	Sweetman SC. <i>Martindale: The Complete Drug Reference, 33rd Edition</i> . London, England: Pharmaceutical Press; 2002.
3.	O'Neil MJ. <i>The Merck Index 12th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 1996.
4.	Vidal 2003. <i>Le Dictionnaire</i> . 79e éd. - Paris : Ed. du Vidal, cop. 2003.
5.	Stoklosa MJ, Ansel HC. <i>Pharmaceutical Calculations</i> . Media, Pennsylvania: Williams and Wilkins; 1996.
6.	<797> <i>Pharmaceutical Compounding - Sterile Preparations</i> . US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXVII / National Formulary 22</i> . Rockville, MD: US Pharmacopeial Convention, Inc.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.